Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R, Stafstrom K, Moshiri A, Yelistratova L, Levinsohn J, Chan TA, Nghiem P, Lifton RP, Choi J. · 2016
Read Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. by Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R, Stafstrom K, Moshiri A, Yelistratova L, Levinsohn J, Chan TA, Nghiem P, Lifton RP, Choi J. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4823115.txt.
Description
Gerald Goh leads a wide author team in Oncotarget in 2016 comparing two kinds of Merkel cell carcinoma, a rare, aggressive skin cancer. About eighty percent of cases carry an integrated virus; the rest do not. The team read the protein-coding genes of 49 tumors to see how the two kinds differ at the DNA level.
The contrast was stark. Virus-free tumors carried over a thousand mutations each, thick in two famous guard genes and in damage-repair and chromatin pathways, a pattern that fits sun exposure. Virus-carrying tumors averaged barely a dozen mutations and none of those faults. The guard gene TP53's state predicted survival sharply in early-stage virus-free disease. Virus-free tumors also displayed far more new protein fragments for the immune system to spot, which backs immune therapy trials for that group.
Catalog record
| CREATOR | Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R, Stafstrom K, Moshiri A, Yelistratova L, Levinsohn J, Chan TA, Nghiem P, Lifton RP, Choi J. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |